LY3532226

Macupatide (LY3532226) is Eli Lilly's long-acting amylin receptor agonist, a once-weekly peptide running in Phase 2 trials for obesity and type 2 diabetes, often paired with eloralintide (LY3841136), Lilly's selective AMY1R agonist. After tirzepatide's runaway commercial success, this is Lilly's next bet on metabolic disease, going after a hormone pathway that complements GLP-1 biology. The commercial question is whether amylin can stack meaningful weight loss on top of incretin drugs, and how macupatide compares to Novo Nordisk's cagrilintide, whose CagriSema (cagrilintide plus semaglutide) Phase 3 REDEFINE-1 readout produced 22.7% weight loss but undershot Novo's own publicly communicated 25% target.

Macupatide is a novel investigational peptide, never approved anywhere. Eli Lilly assigned it the development code LY3532226, and the program is running across at least three active Phase 2 trials enrolling roughly 2,081 participants combined [2][3][4]. None of the trials carry FDA breakthrough therapy, fast track, or orphan designations, which fits the pattern for metabolic drugs where the regulatory path is well-trodden and special designations rarely apply. The Phase 1b data published in Diabetes, Obesity and Metabolism in 2026 showed macupatide preserved insulin sensitivity and beta cell function when given alone or alongside dulaglutide (Lilly's older GLP-1, Trulicity) in T2D patients, with clean tolerability supporting the move to Phase 2 [1]. That readout suggests the drug doesn't induce secondary insulin resistance, and that combining amylin with GLP-1 biology in the same patient is mechanistically clean. Lilly's 2026 10-K groups macupatide with eloralintide as part of a master protocol approach [5]. Phase 2 readouts should land across 2026 and 2027, with a Phase 3 program contingent on whether monotherapy weight loss approaches 15% or whether the combination with eloralintide outperforms tirzepatide-level efficacy. Lilly reported roughly $65 billion in 2025 revenue, with Mounjaro and Zepbound accounting for the dominant share, giving the company unmatched capacity to bankroll multiple amylin shots on goal [5][8].

Amylin is a small hormone that pancreatic beta cells release into the blood at the same time as insulin, whenever blood sugar rises after a meal. It does three things that matter for weight and glucose control. First, it slows gastric emptying, so food sits in the stomach longer and blood sugar rises more gradually. Second, it tells the brain you're full, working through receptors in the hindbrain area postrema. Third, it suppresses glucagon, the hormone that signals the liver to dump glucose into the blood. In type 2 diabetes, amylin secretion collapses along with insulin, leaving these three mechanisms missing in action. Macupatide is engineered as a long-acting amylin analog that binds the calcitonin receptor paired with receptor activity-modifying proteins (RAMPs), the same receptor complex that natural amylin uses [1]. RAMPs are accessory proteins that dock onto the calcitonin receptor and change its shape, creating distinct amylin receptor subtypes (AMY1R, AMY2R, AMY3R) depending on whether RAMP1, RAMP2, or RAMP3 is bound. Different RAMP pairings produce different receptor pharmacology, which is why two amylin-pathway drugs can have meaningfully different biological profiles depending on which subtypes they prefer. Macupatide appears to be a non-selective amylin/calcitonin receptor agonist, similar in profile to cagrilintide. Eloralintide, by contrast, is a selective AMY1R agonist with roughly 12-fold preference for AMY1R over the bare calcitonin receptor [10]. Native amylin clears from blood in minutes; macupatide is built for once-weekly dosing. The case for amylin biology rests on two pieces of evidence. Pramlintide (Symlin), the first amylin analog, was approved in 2005 but required injection with every meal and never became commercially significant [6]. Novo Nordisk's long-acting amylin analog cagrilintide, paired with semaglutide as CagriSema, produced 22.7% weight loss at 68 weeks in the Phase 3 REDEFINE-1 obesity trial, which proves amylin actually adds weight loss on top of GLP-1, even though that number undershot Novo's own publicly communicated 25% threshold and triggered a sharp negative stock reaction [7]. The mechanism is validated, both physiologically (humans missing amylin do worse metabolically) and pharmacologically (a related drug works in late-stage trials). Macupatide's bet is execution and receptor subtype tuning, not whether amylin biology itself works.

Three Phase 2 trials are enrolling. NCT07215559 randomizes 200 adults with obesity or overweight plus type 2 diabetes to macupatide, eloralintide, or the combination, with percent change in body weight as the primary endpoint [2]. NCT07589608 is the parallel obesity trial without the T2D requirement, larger at 400 participants and testing the same three arms [3]. NCT06143956 is the master protocol study (LY900038), enrolling 1,481 participants across multiple intervention-specific appendices including macupatide-containing arms [4]. The primary endpoint of percent body weight change is the standard metric for obesity drugs. The bar Lilly needs to clear is set by tirzepatide's roughly 22.5% weight loss in SURMOUNT-1 at the highest dose, and by CagriSema's 22.7% in REDEFINE-1 obesity and roughly 16% in REDEFINE-2 (the T2D subpopulation, the more directly comparable benchmark for NCT07215559) [7][9]. The trial designs are placebo-controlled but not head-to-head against tirzepatide or semaglutide, which means readouts will need to be cross-referenced to historical comparator data, a weaker form of evidence than direct comparison. The combination arm with eloralintide is the most interesting scientific question, and the rationale is receptor subtype complementarity, not redundancy. Macupatide acts as a non-selective amylin/calcitonin receptor agonist, while eloralintide is selective for AMY1R with about 12-fold preference over the bare calcitonin receptor [10]. Pairing a broad-spectrum amylin agent with a subtype-selective one lets Lilly engage the full amylin pharmacology that the native hormone produces while dialing the AMY1R signal independently, which should produce a different efficacy and tolerability profile than either drug alone. Eloralintide's own Phase 2 monotherapy readout in November 2025 showed 9.5% to 20.1% weight loss across doses at 48 weeks, well above pramlintide-era expectations for the amylin class [11]. The master protocol structure lets Lilly run multiple combinations in parallel without separate trial infrastructure, which is operational scale only a few sponsors can pull off.

Our model estimates a 15% chance this drug is eventually approved. It starts from the historical base rate for Phase 2 drugs in this area (about 35%), then adjusts using ten facts about the trial and sponsor. What moves the number most: it is helped by the sponsor's strong record of getting drugs approved and larger-than-typical enrollment for this phase; it is held back by weak or limited earlier-phase results and a randomized design. The other facts land near average for this stage, so they leave the estimate roughly where the base rate put it.

Efficacy risk runs through the combination arm. Amylin agonists as a class historically produced roughly 8-10% weight loss as monotherapy, but that figure comes from pramlintide-era mealtime data. Eloralintide's November 2025 Phase 2 monotherapy readout showed 9.5% to 20.1% weight loss across doses at 48 weeks, resetting expectations for long-acting selective amylin agents [11]. Macupatide therefore enters Phase 2 with a more demanding bar: monotherapy weight loss in the mid-teens is now the realistic floor, not the ceiling, for the class to remain commercially interesting. If macupatide alone lands below 12%, it competes for a niche of patients who can't tolerate incretins. The combination with eloralintide is justified by receptor subtype complementarity (non-selective plus AMY1R-selective), but Lilly still has to show that the combination beats either component alone by enough to justify two-peptide complexity [10]. Safety risk centers on gastrointestinal tolerability and hypoglycemia. Pramlintide carries a black box warning for severe hypoglycemia when combined with insulin, and any amylin analog used in T2D patients on insulin or sulfonylureas faces the same dose-titration headache [6]. Nausea is the dose-limiting toxicity for both pramlintide and cagrilintide in published trials [6][7]. Long-acting peptides also carry injection site reaction risk that scales with chronic weekly dosing. Execution risk is low for Lilly specifically. The company has run enough metabolic trials to recruit on schedule and run master protocols cleanly. Regulatory uncertainty is also low since FDA has a well-defined path for obesity drugs. Commercial risk is the largest concern. Even with positive Phase 2 data, macupatide enters a market where tirzepatide and semaglutide are entrenched, payers are tightening obesity coverage, and Novo's CagriSema may be approved and on market before macupatide finishes Phase 3 [7][9]. Oral GLP-1 agents (Lilly's own orforglipron and Pfizer's danuglipron, despite earlier safety setbacks for the latter) threaten the injectable combination logic since payers and patients who can take a pill won't readily accept two weekly injections. Zealand Pharma's petrelintide, a long-acting amylin analog also in Phase 2, adds direct in-class competition and could read out on a similar timeline. The differentiated commercial angle for macupatide has to be either superior combination efficacy, better tolerability for incretin-intolerant patients, or an indication outside obesity where amylin has a specific edge.

Worth watching for Lilly franchise depth, not for breakout potential. The genuine question is whether amylin biology adds incremental value on top of incretin saturation, and that question is being answered in real time by REDEFINE-1 (CagriSema obesity, 22.7% versus Novo's 25% target) and REDEFINE-2 (CagriSema T2D, roughly 16%) before macupatide Phase 2 data lands [7][9]. CagriSema sets the bar, and the bar moved down with the REDEFINE-1 miss. Macupatide either matches or beats those numbers or falls into the second tier. The specific data point to watch: head-to-head or cross-trial comparison of macupatide-plus-eloralintide combination weight loss versus tirzepatide and CagriSema. A reasonable Phase 3 go criterion looks like combination weight loss above 18% at 48 weeks with tolerability comparable to tirzepatide. A likely kill criterion is combination weight loss below 14% at 48 weeks or any cardiovascular or pancreatic safety signal. If the combination clears 22% weight loss with clean tolerability, Lilly has another franchise-level asset. If it lands at 15-18%, it becomes a niche product for patients who don't respond fully to incretins. Check back when the first Phase 2 weight loss readout from NCT07215559 or NCT06143956 publishes, likely 2027 [2][4]. Earlier signal will come from any Lilly investor day presentations showing interim Phase 2 weight curves, which the company typically discloses at JPMorgan Healthcare Conference or quarterly earnings calls [5][8]. On exclusivity: as a peptide therapeutic, macupatide is likely to be regulated as a biologic, with 12 years of US biologics exclusivity from approval, plus a composition-of-matter patent estate that Lilly typically files in the early discovery phase and that should retain meaningful patent life through the late 2030s for the LY3532226 series (exact filings not yet public). Lilly's roughly $65 billion in 2025 revenue funds parallel bets across the metabolic field, so macupatide doesn't have to be the next tirzepatide to justify the program. It needs to extend the franchise or fill a tolerability gap, either of which is enough at Lilly's scale.